122 related articles for article (PubMed ID: 6147324)
1. The art of rational neuroleptic therapy.
Ayd FJ
Isr J Psychiatry Relat Sci; 1983; 20(4):292-8. PubMed ID: 6147324
[No Abstract] [Full Text] [Related]
2. Antipsychotic polypharmacy: do benefits justify the risks?
Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
[No Abstract] [Full Text] [Related]
3. Metabolic disturbances associated with antipsychotic use.
Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():3-4; discussion 40-1. PubMed ID: 11806487
[No Abstract] [Full Text] [Related]
4. Drugs for psychotic disorders.
Treat Guidel Med Lett; 2010 Aug; 8(96):61-4; quiz two pages following last numbered page.. PubMed ID: 20651640
[No Abstract] [Full Text] [Related]
5. Low dose therapy: the future of neuroleptic psychopharmacology. A symposium held during the annual meeting of the American Psychiatric Association. May 1986, Washington, D.C.
J Clin Psychiatry; 1986 May; 47 Suppl():1-36. PubMed ID: 2871009
[No Abstract] [Full Text] [Related]
6. [Drug treatment of functional psychotic disorders].
Bridler R; Umbricht D; Hell D
Praxis (Bern 1994); 2001 May; 90(22):981-6. PubMed ID: 11450186
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection: a new strategy in the treatment of schizophrenia. Treatment of first-episode psychosis.
Buckley PF
CNS Spectr; 2007 Oct; 12(10 Suppl 18):7-10. PubMed ID: 19322958
[No Abstract] [Full Text] [Related]
8. [Diagnostic principles for differential therapy of psychoses].
Hell D; Bridler R
Praxis (Bern 1994); 2001 May; 90(22):975-80. PubMed ID: 11450185
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention.
Perkins DO
CNS Spectr; 2007 Oct; 12(10 Suppl 18):10-3. PubMed ID: 19322959
[No Abstract] [Full Text] [Related]
10. Algorithm for the treatment of acute psychotic episodes.
Hayashida M; Nakane Y
Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S3-7. PubMed ID: 10560890
[TBL] [Abstract][Full Text] [Related]
11. Tranquillising actions.
Pollard A; Friedman T; Aslam M
Nurs Times; 1994 Mar 16-22; 90(11):34-6. PubMed ID: 7909149
[No Abstract] [Full Text] [Related]
12. Composition and effects of commonly used neuroleptics.
Culshaw F
Nurs Times; 1994 Sep 21-27; 90(38):38-40. PubMed ID: 7971331
[TBL] [Abstract][Full Text] [Related]
13. The CATIE study and its implications for antipsychotic drug use.
Janicak PG
Essent Psychopharmacol; 2006; 7(1):53-63. PubMed ID: 16989293
[No Abstract] [Full Text] [Related]
14. [Body weight increase: a side effect of zotepin (Nipolept)?].
Wetterling T; Müssigbrodt H
Nervenarzt; 1996 Mar; 67(3):256-61. PubMed ID: 8901286
[TBL] [Abstract][Full Text] [Related]
15. [Neuroleptic drugs and trophic disorders].
Vitorović M; Kobalova M
Nervenarzt; 1984 Jan; 55(1):51-3. PubMed ID: 6143272
[No Abstract] [Full Text] [Related]
16. Neuroleptic drug usage. (Continued education).
Holt RJ
J Pract Nurs; 1983 Mar; 33(3):28-35. PubMed ID: 6132003
[No Abstract] [Full Text] [Related]
17. Introduction. Weight gain with psychotropics: size does matter.
Masand PS
J Clin Psychiatry; 1999; 60 Suppl 21():3-4. PubMed ID: 10548134
[No Abstract] [Full Text] [Related]
18. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
Henderson DC
J Clin Psychiatry; 2001; 62 Suppl 27():10-4; discussion 40-1. PubMed ID: 11806484
[TBL] [Abstract][Full Text] [Related]
19. Legal fallacies of antipsychotic drugs.
Erickson SK; Ciccone JR; Schwarzkopf SB; Lamberti JS; Vitacco MJ
J Am Acad Psychiatry Law; 2007; 35(2):235-46. PubMed ID: 17592170
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic effects of butyrilperazine].
Bohacek N
Neuropsihijatrija; 1964; 12(1-4):133-6. PubMed ID: 16305166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
